Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced...
show moreAuthor | cancerGRACE |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Browse Spreaker Catalogue to discover great new content
Browse Spreaker Catalogue to discover great new content
It's so quiet here...
Time to discover new episodes!